Fundraising FoxK2 HealthVentures — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.
BiotechHealthtechSeattle, US
Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)Andrew Scharenberg(Founder)Michael Jensen(Founder)Philip Low(Founder)Ryan Crisman(Founder)
Co-investorsMPM BioImpactDCVC BioQiming Venture Partners USASoftBank GroupSoftBank Vision FundAlexandria+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ASLAN PharmaceuticalsVBI Vaccines (formerly SciVac Therapeutics)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.